Overall survival (OS) · newly‐diagnosed EOC
Chemotherapy with bevacizumab followed by maintenance bevacizumab showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Overall survival (OS) · platinum‐sensitive recurrent EOC
Chemotherapy with bevacizumab followed by bevacizumab maintenance showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Progression‐free survival · newly‐diagnosed EOC
It is very uncertain whether chemotherapy with bevacizumab followed by maintenance bevacizumab changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).
1 finding from 1 review
Progression‐free survival · platinum‐sensitive recurrent EOC
Chemotherapy with bevacizumab followed by bevacizumab maintenance probably leads to lower progression‐free survival (PFS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
QoL · platinum‐sensitive recurrent EOC
1 finding from 1 review
Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC
Chemotherapy with bevacizumab followed by bevacizumab maintenance leads to higher any adverse event (grade ≥3) compared with chemotherapy alone (high certainty).
1 finding from 1 review
Hypertension (grade ≥ 2) · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Bowel fistula / perforation (grade ≥ 3) · platinum‐sensitive recurrent EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
QoL · newly‐diagnosed EOC
1 finding from 1 review
Adverse events (grade ≥ 3) · newly‐diagnosed EOC
Chemotherapy with bevacizumab followed by maintenance bevacizumab probably leads to higher any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Hypertension (grade ≥ 2) · newly‐diagnosed EOC
Chemotherapy with bevacizumab followed by maintenance bevacizumab may leads to higher hypertension (grade ≥ 2) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Bowel fistula / perforation (grade ≥ 3) · newly‐diagnosed EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Dental caries in children · Children aged 6 to 8 years whose mothers' prenatal vitamin D status was assessed
In the single study of children aged 6-8 years, the association was not statistically significant (OR 1.07, 95% CI 0.84-1.30); ungraded.
1 finding from 1 review
Association between prenatal vitamin D deficiency with dental caries in infants and children: a systematic review and… 2024 All outcomesPrenatal exposure; dental caries at 6 to 8 years · Observational pregnancy/birth-cohort studies (one cross-sectional), mostly in developed countries (USA, Canada, Japan, Australia, Spain, Netherlands, Poland, New Zealand, Turkey) · Children's age subgroup: 6 to 8 years
OR 1.07 [0.84, 1.30]
1 study
GRADE not reported
Dental caries in children · Infants and children (aged about 2 to 8 years) whose mothers' vitamin D status was assessed during pregnancy
Prenatal vitamin D deficiency is associated with significantly higher odds of dental caries in children (pooled OR 1.35, 95% CI 1.22-1.47), but heterogeneity is high (I2=86.6%) and publication bias is present; the observational evidence is ungraded.
2 findings from 1 review
Dental caries in children · Children aged 4 to 6 years whose mothers' prenatal vitamin D status was assessed
Among children aged 4-6 years, prenatal vitamin D deficiency is associated with significantly higher odds of dental caries (OR 1.44, 95% CI 1.32-1.56); ungraded.
1 finding from 1 review
Association between prenatal vitamin D deficiency with dental caries in infants and children: a systematic review and… 2024 All outcomesPrenatal exposure; dental caries at 4 to 6 years · Observational pregnancy/birth-cohort studies (one cross-sectional), mostly in developed countries (USA, Canada, Japan, Australia, Spain, Netherlands, Poland, New Zealand, Turkey) · Children's age subgroup: 4 to 6 years
OR 1.44 [1.32, 1.56]
8 studies
GRADE not reported
Overall survival (OS) · newly‐diagnosed EOC
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in overall survival (OS) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Progression‐free survival (PSF) · newly‐diagnosed EOC
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… showed no clear difference in progression‐free survival (PSF) compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
QoL · newly‐diagnosed EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events (grade ≥ 3) · newly‐diagnosed EOC
Chemotherapy with TKI (peptide‐Fc fusion protein) followed by TKI… probably leads to lower any adverse event grade ≥ 3 compared with chemotherapy alone (moderate certainty).
1 finding from 1 review
Hypertension grade ≥ 3 · newly‐diagnosed EOC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found